AbCellera Biologics has delivered the post-earnings explosion that the crowded short setup was threatening — a 60% weekly surge that has reshuffled every layer of the trade.
The catalyst was the August 10 earnings print. The stock jumped 40.8% the day after results landed, the sharpest single-day move in the recent history. That followed a 7.2% move on August 5, suggesting the market is now reacting strongly to each piece of fundamental news after months of skepticism. The stock closed Tuesday at $9.76, more than double where insiders were buying in February and March at $3.27–$3.44. Bears who held through the rally are sitting on material losses.
Short interest has not broken, which is the key tension now. At 16.1% of the free float — roughly 48 million shares — shorts actually added positions over the past week, with the count rising 5.8%. That is not capitulation; it is rebuilding. The ORTEX short score has climbed to 78.7, the highest reading in the tracked history, up from 77 before earnings. What has changed dramatically is the lending environment: availability has collapsed from 83% a week ago to just 17%, a more than 79% tightening in a single week. Shares available to borrow have dropped to 44 million — nearly one-for-one against the short position itself. Cost to borrow, at 6.2%, remains elevated but not extreme; however, the speed of the availability tightening is the signal worth watching. The borrow pool is thin enough now that any fresh wave of buying could force covering.
Options traders noticed. The put/call ratio jumped to 0.43 on Tuesday, more than 2.5 standard deviations above its 20-day average of 0.37 — the most elevated defensive reading in the recent series. That is a notable shift: even as the stock rockets higher, someone is buying meaningful downside protection. Whether that represents shorts hedging their rebuilt position or longs locking in gains is unclear, but the options market is more charged than it has been all summer.
The analyst reaction to earnings has been decisive and lopsided to the upside. Truist Securities raised its target from $12 to $30 on August 11 — a 150% increase — while maintaining its Buy rating. That single move reset the Street's center of gravity. Stifel and Cantor Fitzgerald both lifted targets modestly in the days just after the prior print. The consensus now sits at Buy across seven analysts, with a mean target of $17.43. At $9.76, that implies substantial upside on the Street's own math — though some of those targets will be stale within days as analysts reprice post-earnings. The bull case centers on active discovery partnerships with Jazz and Vertex, more than 20 programs in flight, and the company's position in next-generation multispecific antibodies. Bears have focused on limited clinical data disclosure and a long timeline to commercialization, with first approvals potentially not arriving until 2027.
Institutional ownership adds an interesting layer. CEO and founder Carl Hansen holds 18.6% of shares, and Baker Bros. Advisors — a healthcare-specialist fund — added 28 million shares to reach a 9.9% stake, last reported in April. That is a substantial, concentrated bet from a sophisticated life-sciences investor. The insider trade log is entirely purchases: Hansen bought in February at $3.27–$3.44, and the CFO joined him. Those buyers are now sitting on gains above 180%. No insider has sold.
The next earnings event is flagged for November 6. Between now and then, the story is whether shorts — who rebuilt through a 60% rally — hold their conviction as availability tightens further, or whether a continued grind higher forces a second wave of covering that the borrow market may not be able to absorb cleanly. Peer TKNO is up 27% on the week and TEM gained 18%, suggesting broader sentiment in the antibody and life-sciences platform space has turned; QTRX bucked that trend with a 29% weekly decline, a reminder of how quickly sentiment can reverse for clinical-stage names. The tightening borrow pool, an analyst community repricing rapidly to the upside, and a short position that has not broken despite a 60% move is a setup that warrants close attention into next week.
See the live data behind this article on ORTEX.
Open ABCL on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
